STAT Plus: With positive early results, Sarepta appears to have a second gene therapy with potential
RUBY WALLAU FOR STAT
Sarepta Therapeutics announced early but encouraging results from its second gene therapy program targeting a rare, muscle-wasting disease.
No hay comentarios:
Publicar un comentario